SURVEY OF PTH, CANXIUM, PHOSPHORUS, AND HEMOGLOBIN CONCENTRATIONS IN PATIENTS WITH CHRONIC KIDNEY DISEASE TREATED BY PERITONEAL DIALYSIS AND PERIODIC HEMODIALYSIS
Main Article Content
Abstract
Objective: To survey biochemical parameters, including parathyroid hormone, canxium, phosphorus, and hemoglobin in patients with end-stage renal disease undergoing either hemodialysis or peritoneal dialysis, to evaluate the effectiveness of mineral metabolism control and anemia management according to KDIGO (2012) guidelines.
Subjects and methods: A cross-sectional descriptive study was conducted on 185 patients at the Department of Nephrology - Dialysis, Thong Nhat Hospital, comprising 57 on peritoneal dialysis and 128 on hemodialysis, from November 2022 to October 2024. Biochemical parameters were analyzed and compared between the 2 groups using appropriate statistical methods.
Results: There was no statistically significant difference between the hemodialysis and peritoneal dialysis groups in any of the parameters (parathyroid hormone, canxium, phosphorus, hemoglobin). Peritoneal dialysis showed better phosphorus control than hemodialysis with a median 1.5 mmol/L (1.09-1.91) vs. 1.75 mmol/L (1.375-2.125), p < 0.05). A mild positive correlation between parathyroid hormone and hemoglobin was observed in the peritoneal dialysis group (rho = 0.268; p < 0.05). Achievement rates according to KDIGO (2012) targets: parathyroid hormone ~60%, canxium > 50%, hemoglobin > 33%, phosphorus lowest (10.7-15.8%), Ca × P > 98%.
Conclusion: Both dialysis modalities demonstrated comparable effectiveness in controlling biochemical parameters according to KDIGO (2012) guidelines. Peritoneal dialysis demonstrated superior phosphorus removal and may offer benefits for improving anemia status.
Article Details
Keywords
Parathyroid hormone, hemodialysis, peritoneal dialysis, end-stage chronic kidney disease.
References
[2] Evenepoel P, Bover J, Torres P.U. Parathyroid hormone metabolism and signaling in health and chronic kidney disease. Kidney International, 2016, 90 (6): 1184-90.
[3] Nguyễn Thanh Minh. Nghiên cứu rối loạn xương, khoáng và các yếu tố liên quan trên bệnh nhân bệnh thận mạn giai đoạn 5 lọc máu chu kỳ. Luận án tiến sĩ y học, Trường Đại học Y Dược, Đại học Huế, 2021.
[4] Ketteler M, Evenepoel P, Holden R.M, Isakova T, Jørgensen H.S, Komaba H et al. Chronic kidney disease-mineral and bone disorder: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney International, 2025, 107 (3): 405-23.
[5] Block G.A, Klassen P.S, Lazarus J.M, Ofsthun N, Lowrie E.G, Chertow G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Journal of the American Society of Nephrology, 2004, 15 (8): 2208-18.
[6] Nguyễn Như Nghĩa, Nguyễn Thị Diễm Thúy. Tác động của cường cận giáp thứ phát trong điều trị thiếu máu ở bệnh nhân lọc máu chu kỳ: nghiên cứu bệnh chứng. Tạp chí Y học Việt Nam, 2025, 547 (1): 334-339. doi: 10.51298/vmj.v547i1.12917
[7] Hecking M, Bieber B.A, Ethier J, Kautzky-Willer A, Sunder-Plassmann G, Säemann M.D et al. Sex-specific differences in hemodialysis prevalence and practices and the male-to-female mortality rate: the dialysis outcomes and practice patterns study (DOPPS). PLoS Medicine, 2014, 11 (10): e1001750.
[8] Evenepoel P, Meijers B.K, Bammens B, Viaene L, Claes K, Sprangers B et al. Phosphorus metabolism in peritoneal dialysis- and haemodialysis-treated patients. Nephrol Dial Transplant, 2016, 31 (9): 1508-14.
[9] Lê Thị Đan Thùy. Khảo sát nồng độ canxi, phốt pho, hormon tuyến cận giáp ở người bệnh thận mạn lọc máu chu kỳ và lọc màng bụng liên tục ngoại trú tại Bệnh viện Bình Dân. Luận văn bác sĩ chuyên khoa II, chuyên ngành Nội khoa. Đại học Y Dược thành phố Hồ Chí Minh, 2019.
[10] Chutia H, Ruram A.A, Bhattacharyya H, Boruah P, Nath C. Association of secondary hyperparathyroidism with hemoglobin level in patients with chronic kidney disease. Journal of Laboratory Physicians, 2013, 5 (01): 51-4.